The results of previous cardiovascular outcome trials (CVOTs) indicated that SGLT2 inhibitors improve kidney outcomes in patients with type 2 diabetes (T2D) and normal renal function, thereby leading to the initiation of multiple trials on kidney outcomes that enrolled patients with advanced CKD (CREDENCE, DAPA-CKD, and the Study of Heart and Kidney Protection with Empagliflozin [EMPA-KIDNEY]) [15,16]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.